-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Benzinga·08/04/2026 11:48:50
Listen to the news
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.